McDonough Christine M, Tosteson Anna N A
Dartmouth Medical School, Multidisciplinary Clinical Research Center in Musculoskeletal Diseases, Lebanon, New Hampshire 03756, USA.
Pharmacoeconomics. 2007;25(2):93-106. doi: 10.2165/00019053-200725020-00003.
Preferences for health are required when the economic value of healthcare interventions are assessed within the framework of cost-utility analysis. The objective of this paper was to review alternative methods for preference measurement and to evaluate the extent to which the method may affect healthcare decision-making. Two broad approaches to preference measurement that provide societal health state values were considered: (i) direct measurement; and (ii) preference-based health state classification systems. Among studies that compared alternative preference-based systems, the EQ-5D tended to provide larger change scores and more favourable cost-effectiveness ratios than the Health Utilities Index (HUI)-2 and -3, while the SF-6D provided smaller change scores and less favourable ratios than the other systems. However, these patterns may not hold for all applications. Empirical evidence comparing systems and decision-making impact suggests that preferences will have the greatest impact on economic analyses when chronic conditions or long-term sequelae are involved. At present, there is no clearly superior method, and further study of cost-effectiveness ratios from alternative systems is needed to evaluate system performance. Although there is some evidence that incremental cost-effectiveness ratio (ICER) thresholds (e.g. $US50,000 per QALY gained) are used in decision-making, they are not strictly applied. Nonetheless, as ICERs rise, the probability of acceptance of a new therapy is likely to decrease, making the differences in QALYs obtained using alternative methods potentially meaningful. It is imperative that those conducting cost-utility analyses characterise the impact that uncertainty in health state values has on the economic value of the interventions studied. Consistent reporting of such analyses would provide further insight into the policy implications of preference measurement.
在成本效用分析框架内评估医疗保健干预措施的经济价值时,需要对健康偏好进行考量。本文的目的是回顾偏好测量的替代方法,并评估这些方法可能影响医疗保健决策的程度。我们考虑了两种提供社会健康状态值的偏好测量的广泛方法:(i)直接测量;(ii)基于偏好的健康状态分类系统。在比较基于偏好的替代系统的研究中,与健康效用指数(HUI)-2和-3相比,EQ-5D往往能提供更大的变化分数和更有利的成本效益比,而SF-6D提供的变化分数更小,比率也不如其他系统有利。然而,这些模式可能并不适用于所有应用。比较系统和决策影响的实证证据表明,当涉及慢性病或长期后遗症时,偏好对经济分析的影响最大。目前,没有明显优越的方法,需要对替代系统的成本效益比进行进一步研究,以评估系统性能。虽然有一些证据表明决策中使用了增量成本效益比(ICER)阈值(例如每获得一个质量调整生命年50,000美元),但并未严格应用。尽管如此,随着ICER的上升,接受新疗法的可能性可能会降低,使得使用替代方法获得的质量调整生命年的差异可能具有意义。进行成本效用分析的人员必须描述健康状态值的不确定性对所研究干预措施的经济价值的影响。对这类分析进行一致的报告将为偏好测量的政策含义提供进一步的见解。